Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Pharmaco-genomics Pharmaco-metabolomics Pharmaco-transcriptomics Pharmaco-proteomics Search

Displaying entries 79701 - 79725 of 102031 in total

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome	References
							Clear
Titanium dioxide	Approved	IL1B	3553	upregulated	titanium dioxide results in increased expression of IL1B mRNA	2q14.1	A24217
Titanium dioxide	Approved	IL1RAP	3556	upregulated	titanium dioxide results in increased expression of IL1RAP mRNA	3q28	A24217
Titanium dioxide	Approved	IL4	3565	upregulated	titanium dioxide results in increased expression of IL4 mRNA	5q31.1	A24434
Titanium dioxide	Approved	IL5	3567	upregulated	titanium dioxide results in increased expression of IL5 mRNA	5q31.1	A24434
Titanium dioxide	Approved	IL6	3569	downregulated	titanium dioxide results in decreased expression of IL6 mRNA	7p15.3	A24217
Titanium dioxide	Approved	IRAK1	3654	upregulated	titanium dioxide results in increased expression of IRAK1 mRNA	Xq28	A24217
Titanium dioxide	Approved	IRAK2	3656	downregulated	titanium dioxide results in decreased expression of IRAK2 mRNA	3p25.3	A24217
Titanium dioxide	Approved	IRF1	3659	upregulated	titanium dioxide results in increased expression of IRF1 mRNA	5q31.1	A24217
Titanium dioxide	Approved	ITGA5	3678	upregulated	[Vitallium analog binds to titanium dioxide] which results in increased expression of ITGA5 mRNA	12q13.13	A24432
Titanium dioxide	Approved	ITGAV	3685	upregulated	titanium dioxide results in increased expression of ITGAV mRNA	2q32.1	A24440
Titanium dioxide	Approved	ITGB6	3694	upregulated	titanium dioxide results in increased expression of ITGB6 mRNA	2q24.2	A24434
Titanium dioxide	Approved	KRT6A	3853	downregulated	titanium dioxide results in decreased expression of KRT6A mRNA	12q13.13	A24441
Titanium dioxide	Approved	LAMA5	3911	upregulated	[Vitallium analog binds to titanium dioxide] which results in increased expression of LAMA5 mRNA	20q13.33	A24432
Titanium dioxide	Approved	LTBP1	4052	upregulated	[Vitallium analog binds to titanium dioxide] which results in increased expression of LTBP1 mRNA	2p22.3	A24432
Titanium dioxide	Approved	MAPK14	1432	upregulated	titanium dioxide results in increased expression of MAPK14 mRNA	6p21.31	A24217
Titanium dioxide	Approved	MAPK3	5595	upregulated	[Vitallium analog binds to titanium dioxide] which results in increased expression of MAPK3 mRNA	16p11.2	A24432
Titanium dioxide	Approved	MAPK8	5599	upregulated	titanium dioxide results in increased expression of MAPK8 mRNA	10q11.22	A24217
Titanium dioxide	Approved	MDM2	4193	upregulated	titanium dioxide results in increased expression of MDM2 mRNA	12q15	A24437
Titanium dioxide	Approved	MFAP2	4237	upregulated	[Vitallium analog binds to titanium dioxide] which results in increased expression of MFAP2 mRNA	1p36.13	A24432
Titanium dioxide	Approved	MKI67	4288	downregulated	[Vitallium analog binds to titanium dioxide] which results in decreased expression of MKI67 mRNA	10q26.2	A24432
Titanium dioxide	Approved	MMP1	4312	upregulated	[Vitallium analog binds to titanium dioxide] which results in increased expression of MMP1 mRNA	11q22.2	A24432
Titanium dioxide	Approved	MMP10	4319	upregulated	titanium dioxide results in increased expression of MMP10 mRNA	11q22.2	A24434
Titanium dioxide	Approved	MMP7	4316	upregulated	titanium dioxide results in increased expression of MMP7 mRNA	11q22.2	A24434
Titanium dioxide	Approved	MMP9	4318	upregulated	titanium dioxide results in increased expression of MMP9 mRNA	20q13.12	A24434
Titanium dioxide	Approved	MSH6	2956	downregulated	[Vitallium analog binds to titanium dioxide] which results in decreased expression of MSH6 mRNA	2p16.3	A24432

Displaying entries 79701 - 79725 of 102031 in total

Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Advanced Filter

Filter by Group

Filter by Market Availability